Business
Marizyme, Inc. Hires Ralph Makar as Chief Executive Officer
Marizyme, Inc. Hires Ralph Makar as Chief Executive Officer.
About this update from Marizyme, Inc.
[{"type":"text","content":"JUPITER, FLA, February 24, 2020 — Marizyme, Inc. (“Marizyme” or the “Company”), a publicly traded (OTC:MRZM) company focused on acquiring late-stage drug and medical device assets to develop for use in the acute care space, announced today that Ralph Makar will be joining Marizyme, Inc. on or about April 1, 2020, as Chief Executive Officer (CEO), bringing more than 35 years of industry experience to the Company. Mr. Makar is a successful life sciences executive with both US and global experience in general management, strategic leadership and business development, as well as in raising capital for both startup and established organizations. Ralph has been leading all business and R&D efforts at iDrug Delivery Inc. as President and CEO since December 2017. He continues to serve as executive and board advisor to select organizations. Ralph Makar’s efforts have resulted in the exceptional growth of multiple billion dollar blockbuster brands (e.g., Diovan®, Lipitor®, Voltaren®) through innovative strategic leadership supported by securing hundreds of millions of dollars in resources. In addition to his accomplishments in large corporate pharmaceutical organizations, Ralph has also delivered excellence in smaller startup ventures and has managed a public company as CEO. Mr. Nicholas DeVito will resign as Interim Chief Executive Officer upon Mr. Makar’s arrival and will remain as Chief Financial Officer.“We are fortunate to have such a seasoned pharmaceutical and medical device veteran join the Marizyme team,” said James Sapirstein, Marizyme’s Executive Chairman. “Mr. Makar’s experience with specialty pharmaceuticals and medical devices brings significant added value to the Company and will help the organization implement our growth strategies and drive the Company forward. We thank Mr. DeVito for his continued leadership and his agreement to remain as our CFO. He has been an invaluable contributor to Marizyme since its inception.”“I am excited and honored to be joining Marizyme, Inc. at such an opportune time to build the organization and increase shareholder value” stated Mr. Makar. “The Company has significant potential to develop new products that can benefit patients and improve medical outcomes.”About Marizyme, Inc.Marizyme, Inc. is a development-stage company dedicated to the c...